Ocugen and the "Orphan drug designation from the
Ocugen scientific founder and board member
Ocugen licensed all assets related to LEDGF, including LEDGF1- 326 and OCU200, an anti-angiogenic tumstatin fusion protein, to be developed for treatment of wet age-related macular degeneration from the
"OCU100 has shown the potential as a promising therapeutic agent for treating retinitis pigmentosa by reducing protein aggregation and associated cellular stresses, which are known to contribute to this condition," said Kompella. "With impressive preclinical data, we look forward to progressing with a phase 1 study for safety and tolerability in patients sometime in 2015."
The Company said
((Comments on this story may be sent to firstname.lastname@example.org))
Ocugen and the
"Orphan drug designation from the